Net sales grew 7.5% to EUR 603 million in H1 2026, with EBITDA margin reaching 25% and strong European dermatology performance. Guidance for 2026 is reiterated, with key products Ilumetri and Ebglyss maintaining momentum and a robust pipeline advancing in immune-mediated skin diseases.Based on Almi…
Net turnover grew 7.5% to €602.75 million, driven by dermatology sales in Europe, with profit after tax up 37.9% to €60.9 million. Strong operating cash flow increased liquidity to €354.6 million, and R&D advanced with positive Phase 3 results for Ebglyss.Original document: Almirall SA [ALM] Interi…
Net sales rose 7.5% year-over-year to €602.7 million, led by strong European dermatology growth and robust biologics performance. EBITDA margin improved to 25.0%, and the pipeline advanced with six proof-of-concept/Phase II programs. Moody's upgraded the credit rating to Ba1.Original document: Almi…
Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its financial results for the first half of 2026. The company delivered solid H1 2026 results, with Net Sales growing 7.5% YoY to €602.7 MM and EBITDA increasing 23.7% YoY to €150.7 MM. The resul…
Almirall SA BME:ALM:Source text
